D. Boral Capital Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $24.00 price target on the stock. D. Boral Capital’s price objective points to a potential upside of 181.03% from the stock’s previous close.

A number of other brokerages have also issued reports on IBRX. BTIG Research boosted their price target on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Piper Sandler increased their price target on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. HC Wainwright increased their target price on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Jefferies Financial Group raised their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

ImmunityBio Price Performance

ImmunityBio stock opened at $8.54 on Tuesday. The stock has a market cap of $8.41 billion, a price-to-earnings ratio of -20.83 and a beta of 0.16. ImmunityBio has a 1 year low of $1.83 and a 1 year high of $8.68. The firm has a 50-day moving average of $4.22 and a two-hundred day moving average of $3.03.

Insider Transactions at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 151,967 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the transaction, the director directly owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 226,967 shares of company stock valued at $1,531,912 over the last quarter. 69.48% of the stock is currently owned by corporate insiders.

Institutional Trading of ImmunityBio

Several hedge funds and other institutional investors have recently made changes to their positions in IBRX. Armistice Capital LLC acquired a new position in ImmunityBio during the 2nd quarter valued at about $20,497,000. AlphaCore Capital LLC purchased a new stake in shares of ImmunityBio during the second quarter worth about $7,854,000. Geode Capital Management LLC increased its holdings in shares of ImmunityBio by 34.7% during the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock valued at $15,254,000 after acquiring an additional 1,487,849 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of ImmunityBio in the 2nd quarter valued at approximately $70,000. Finally, CWM LLC boosted its stake in ImmunityBio by 849.2% in the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock worth $129,000 after purchasing an additional 43,583 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European Commission granted conditional marketing authorization for ANKTIVA to treat bladder cancer — a clear regulatory catalyst that expands the drug’s addressable market in the EU. Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer
• Positive Sentiment: EU authorization is part of a rapid international rollout (now in 33 countries) that gives ImmunityBio a faster path to scale commercial revenue across multiple jurisdictions. What’s Behind The Jump In ImmunityBio Stock?
• Positive Sentiment: Productive regulatory engagement and filings in Saudi Arabia (including prior nods) further expand market access in the Middle East and support near‑term commercial upside. ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority
• Positive Sentiment: Commercial traction is improving: FY25 revenue for ANKTIVA was reported at roughly $113M (~700% YoY growth), supporting the bull case that approval-driven expansion can drive meaningful top-line growth. ImmunityBio: The Story Surrounding Anktiva So Far
• Positive Sentiment: Analyst support: at least one shop reaffirmed a buy rating with a $24 price target, giving investors a visible upside benchmark. Benzinga
• Neutral Sentiment: Upcoming pivotal trial readouts (additional bladder-cancer cohorts, glioblastoma) are important catalysts — positive results could lift valuation further, while misses would be punitive. ImmunityBio: The Story Surrounding Anktiva So Far
• Neutral Sentiment: Trading dynamics: the move is accompanied by much higher-than-average volume, which can amplify short-term momentum but also increases volatility. ImmunityBio stock soars after EU authorization for bladder cancer therapy
• Negative Sentiment: Pomerantz law firm announced an investor investigation into ImmunityBio — a legal overhang that could create headline risk and potential costs if litigation proceeds. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. – IBRX

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.